Trasylol® Used in Coronary Artery Bypass Graft Surgery Linked to Kidney Failure
We are currently investigating potential claims for injuries suffered as a result of patients being given Trasylol® (aprotinin), which is used to control bleeding and the need for blood transfusions during coronary artery bypass grafting (CABG) surgery. Trasylol®, manufactured by Bayer, has recently been in the spotlight over recent studies that suggest the drug causes an increase in the risk of serious kidney damage, heart attack, stroke, and death.
A Trasylol® study done by Dennis Mangano, MD was published in the January 2006 edition of the New England Journal of Medicine showed Trasylol® was associated with a doubling in the risk of kidney failure requiring dialysis among patients undergoing coronary artery surgery. The study also concluded that replacing Trasylol® with one of two safe generic drugs would annually prevent as many as 11,050 dialysis complications, save $1 billion in healthcare costs, and reduce drug costs by $250 million. Another study published in the journal Transfusion, also suggested that Trasylol® increased the risk for renal dysfunction or failure.
In September 2006, the Food and Drug Administration (FDA) learned of another study conducted by Bayer a week after a FDA Cardiovascular and Renal Drugs Advisory Committee meeting. The newly discovered study reported that use of Trasylol® may increase the chance for serious kidney damage, strokes, congestive heart failure, and death. The FDA also announced that Bayer had failed to reveal the results of this Trasylol® study.
In light of the aforementioned Trasylol® studies, the FDA is revaluating the safety and benefits of Trasylol® more closely to determine if labeling changes or other actions are needed.
If you or someone you know has undergone a coronary artery bypass graft surgery and subsequently developed kidney damage or failure, please use the form on the left to contact our law firm.
Trasylol® Patient Information Sheet
